Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

July 19, 2002



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Omapatrilat in the Treatment of Hypertension, Dr. Anthony Waclawski, PhD, Pharmaceutical Research Institute htm  ppt

Efficacy and Safety, Dr. Elliott Levy, MD, Pharmaceutical Research Institute  htm  ppt

Overture, Dr. Milton Packer, MD, FACC, Columbia Presbyterian Medical Ctr.  htm  ppt

Clinician's Perspective, Dr. Henry Black, MD FACP, Rush-Presbyterian-St. Luke' Medical Ctr.  htm  ppt

Additional Information  htm  ppt